ValorQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25TTMGastos comerciales, generales y administrativos4.4 M4.86 M4.56 M4.19 M4.85 M18.46 MInvestigación y desarrollo3.42 M3.11 M3.11 M3.27 M8.24 M17.73 MBeneficio operativo-5.11 M-6.5 M-19.78 M-3.79 M-6.55 M-36.62 MTotal de ingresos no operativos1.86 M2.36 M-10.58 M-25.97 M2.16 M-32.03 MGastos por intereses, netos de intereses capitalizados——————Ingresos no operativos, una vez deducidos los gastos por intereses2.55 M2.55 M-10.61 M-25.97 M2.13 M-31.9 MIngresos/gastos extraordinarios-689 K-185 K26 K027 K-132 KBeneficio antes de impuestos-3.25 M-4.14 M-30.36 M-29.75 M-4.39 M-68.65 MParticipación en los beneficios——————Impuestos0000-7.13 M-7.13 MParticipación minoritaria23 K-4 000100 K29 K41 K166 KOtros ingresos/gastos después de impuestos——————Beneficio neto antes de actividades interrumpidas-3.27 M-4.14 M-30.46 M-29.78 M851 K-63.53 MOperaciones suspendidas——————Beneficio neto-3.27 M-4.14 M-30.46 M-29.78 M851 K-63.53 MAjuste por dilución——————Dividendos de las acciones preferentes——————Beneficio neto diluido atribuible a los accionistas-3.27 M-4.14 M-30.46 M-29.78 M851 K-63.53 MBeneficio básico por acción0-0.02-0.13-0.13-0-0.28Beneficio por acción diluido0-0.02-0.13-0.13-0-0.28Número medio de acciones ordinarias200.19 M226.05 M228.36 M228.85 M230.12 M913.38 MAcciones diluidas200.19 M226.05 M228.36 M228.85 M230.12 M913.38 MEBITDA49.87 M-6.49 M-19.77 M-3.77 M-6.53 M-36.56 MEBIT-5.11 M-6.5 M-19.78 M-3.79 M-6.55 M-36.62 MCosto de los ingresos154 K36 K————Otros costes de producción——————Amortización y depreciación (flujo de caja)54.98 M14 K14 K15 K16 K59 K
Lineage Cell Therapeutics Inc
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer.